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THE IMPACT OF THE DRUG CATEGORIZATION ON THE 
PRESCRIPTION AND CONSUMPTION OF NONSTEROIDAL 
ANTIINFLAMATORY DRUGS (NSAID)
Gatialová K, Petrová L, Bellová K, Majtás J, Foltan V
Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic
OBJECTIVES: This study deals with the impact of regulatory measures represented 
by the drug categorization on the prescription and at the use of nonsteroidal and 
antiinﬂ ammatory drugs (NSAID) and asses measures of the state health policy and 
their application in the Slovak Republic within year 2009. METHODS: Analysis was 
conducted with key data represented by the medicine name and code, name of registra-
tion decision owner, maximum price of producer and importer, ﬁ nal medicine price, 
maximum copayment, prescription and indication restriction, the number of medicine 
packages. As data sources were used The List of Drugs. Analysis of categorizations in 
ATC group of drugs M01- NSAID, comparison of single changes and its signiﬁ cance. 
RESULTS: In year 2009 were 9,087,217 medicine packages from the group of NSAID 
expended. From this amount of medicine packages were 2,477,352 packages expended 
during ﬁ rst quartal of 2009, which represents the highest consumption of all four 
terms. The lowest consumption was noticed in period of second term reaching expen-
diture of only 2,020,514 medicine packages. Outstanding changes appeared by indo-
metacine where prescription decreased from 9782 medicine packages to zero. 
Lornoxicam has appeared in third term as new medicine in categorization and his 
consumption increased to 3091 medicine packages in the fourth term. In all four terms 
dominated the same drugs on ﬁ rst ten places of medicine consumption (ibuprofen, 
diclofenac, nimesulid, combinations of ibuprofen, meloxicam, ketoprofen, ﬂ urbipro-
fen, piroxicam, naproxen, aceclofenac). CONCLUSIONS: Current state of categoriza-
tion and functioning of professional bodies represent initial assumption of health 
policy asserting. Patient registries are helping tool in assessing effectiveness of medi-
cines and cost efﬁ cacy and should be legislated. There is a disadvantage of administra-
tive burden. Patient co- payment has increasing tendency due to removing responsibility 
for own health on patients.
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CONSUMPTION OF BISPHOSPHONATES FOR THE TREATMENT OF 
OSTEOPOROSIS
Vytrisalova M, Blazkova S
Charles University, Faculty of Pharmacy, Hradec Kralove, Czech Republic
OBJECTIVES: The objective was to analyze trends in the consumption of bisphos-
phonates for the treatment of osteoporosis in 2002–2006. METHODS: The prescrip-
tion-based database of the General Health Insurance Company of the Czech Republic 
(VZP CR), the largest health insurance company of the Czech Republic that covers 
about 65% of the Czech population, was used as the source of data from 2002–2006. 
Health insurance is compulsory under Czech law. In 2002–2006, alendronate and 
risedronate (in both once-daily and once-weekly formulations) were available for the 
treatment of osteoporosis. The prescription of the two bisphosphonates is restricted 
to specialists in internal medicine, orthopaedy, rheumatology, gynecology and endo-
crinology. RESULTS: In 2002–2006, as many as 63 251 (0.94%) and 21 064 (0.31%) 
patients (insured persons) reﬁ lled at least one prescription for alendronate and rise-
dronate, respectively. Men accounted for 3% of the bisphosphonate consumption. 
The age of bisphosphonate consumers was 69 years (median). Bisphosphonates were 
prescribed most often by physicians specializing in internal medicine, orthopaedy and 
rheumatology. The mean alendronate and risedronate consumption rates were 5.2 and 
1.5 deﬁ ned daily doses (DDD)/1000 insured persons/day, respectively. Mean DDD per 
year/patient was higher in women than in men (204 versus 186 for alendronate and 
179 versus 172 for risedronate). The number of patients on alendronate increased by 
83% from 2002 to 2006. CONCLUSIONS: Signals of inadequate osteoporosis treat-
ment in the Czech population in 2002–2006 were found. The consumption of bisphos-
phonates is particularly low in men. The increasing consumption rates of alendronate 
could be considered as a positive trend. The project was fully supported by grant No. 
103107 (2007–2009) from the Charles University Grant Agency.
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RETROSPECTIVE OBSERVATIONAL DATABASE ANALYSIS OF TNF-Á 
INHIBITOR SWITCHING PATTERNS IN PATIENTS IN THE UNITED 
STATES WITH RHEUMATOID ARTHRITIS IN TWO DISTINCT 
“NATURALISTIC” TREATMENT SETTINGS USING A PRE-PROGRAMMED 
DATA ANALYSIS TOOL
Chiappinelli R1, McNeeley B1, Byrd J2, Ollinger E2
1HealthCore, Wilmington, DE, USA; 2Dymaxium, Inc, Toronto, ON, Canada
OBJECTIVES: Evaluate 12 month switch patterns among patients taking anti-TNFs 
for rheumatoid arthritis (RA) in the context of validating a Rheumatoid Arthritis 
Outcomes Analyzer (RAOA); a data analysis tool incorporating pharmacy, medical 
claims, and member eligibility information. METHODS: The study was conducted 
utilizing claims data from a two large commercial data sets: Cohorts #1 and #2. 
Facilitated by the RAOA, medical and pharmacy claims were entered into two distinct 
data sets for inclusion in the analysis. Patients were ≥18 years of age, received ≥ one 
traditional (non-biologic) or biologic DMARD between January 2005 and December 
2007, and had ≥ two RA diagnoses (ICD-9 CM 714.0X) ≥ two months apart. For the 
switch analysis, patients had at least 18 months continuous eligibility; 6 months prior 
to index date (initial anti-TNF) and treatment naïve, and 12 months post. RESULTS: 
A total of 2177 (Cohort #1) vs. 1113 (Cohort #2) patients entered the analysis. In 
Cohort #1, 426 (19.6%) received adalimumab, 1123 (51.6%) received etanercept and 
628 (28.8%) received inﬂ iximab as initial treatment. In Cohort #2, 355 (31.9%) 
received adalimumab, 509 (45.7%) received etanercept and 249 (22.4%) received 
inﬂ iximab. In both Cohorts, 75% were female. During the twelve months following 
the index date, 161 (7.4%) vs. 91 (8.2%) switched to another biologic DMARD; 133 
(6.1%) vs. 87 (7.8%) switched to another anti-TNF biologic and 28 (1.3%) vs. 4 
(0.4%) to a non anti-TNF biologic DMARD. Twenty-seven (6.3%) vs. 44 (12.4%) 
of patients in the adalimumab sub-group switched to an anti-TNF biologic compared 
to 99 (8.8%) vs. 37 (7.3%) for etenercept and 7 (1.1%) vs. 6 (2.4%) for inﬂ iximab. 
CONCLUSIONS: Analytic tools such as the RAOA will allow payers and policy 
makers to better understand utilization and treatment patterns easily and quickly. 
Replication and validation of outputs from these tools are important to establish the 
precision of results.
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PENETRATION OF MONOCLONAL ANTIBODIES ONTO FINNISH 
PHARMACEUTICAL MARKET
Kannisto HE1, Jormanainen V1, Happonen P2
1Finnish Medicines Agency (Fimea), Helsinki, Finland; 2Finnish Medicines Agency (Fimea), 
Kuopio, Finland
OBJECTIVES: Monoclonal antibodies (MAB) are biomedicines used for treatment of 
cancer, rheumatoid arthritis, psoriasis and inﬂ ammatory intestinal diseases. Since the 
ﬁ rst market entry in 1996 in Finland, their sales have increased continuously. We 
describe the penetration of MABs onto the Finnish pharmaceutical market in 1996–
2009. METHODS: The sales of MABs (wholesale ﬁ gures in million euros, c M) with 
marketing authorization were extracted by calendar year from the market database 
SLD Pharma (Finnish Pharmaceutical Data Ltd.) based on active substances. Annual 
ﬁ gures were converted into 2009 values with the annually-updated Finnish National 
Pensions index (Social Insurance Institution). RESULTS: In 2009, the sales of the 17 
MABs were c109 M or 5.6% of the total pharmaceutical market value (c1900 M). 
On the hospital market (73% of MAB sales in 2009), however, the respective share 
was 16% following a steady increase in 1999–2009. Up to the end of 2009, the overall 
cumulative MAB sales exceeded c479 M. Inﬂ iximab showed the highest cumulative 
sales of c120 M (entry in 1999). Adalimumab penetrated the market even more 
rapidly, with cumulative sales of c109 M (entry in 2003), and became the most-sold 
active substance in 2009 in Finland. The third MAB exceeding cumulative sales of 
c100 M was rituximab (entry in 1998). In terms of ﬁ rst-year sales, adalimumab was 
the most successful MAB, amounting to over c6 M. Bevacizumab achieved the second-
highest ﬁ rst-year sales (c1.8 M in 2005), while the third MAB exceeding c1 M sales 
was ranibizumab (c1.7 M in 2007). CONCLUSIONS: The penetration of several 
MABs onto the Finnish pharmaceutical market has been very successful within a short 
period of time.
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CONJOINT ANALYSIS OF REDUCTION OF CO-PAYMENT RATE OF 
NATIONAL HEALTH INSURANCE SYSTEM IN JAPAN
Igarashi A1, Kikuta K1, Hoshi D2, Tanaka E2, Yamanaka H2, Tsutani K1
1Grad. Sch. of Pharm, University of Tokyo, Tokyo, Japan; 2Tokyo Women’s Medical 
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BACKGROUND: In Japanese national health insurance system, there is some limit 
for monthly co-payment amount. In some diseases, AIDS, chronic renal failure with 
dialysis and hemophilia, co-payment limits are additionally reduced. Patient groups 
for myeloma, cervical cancer, hepatitis, chronic myelogenous leukemia and rheuma-
toid arthritis argued that co-payment reduction should be implemented to their dis-
eases. OBJECTIVES: To conduct conjoint analysis to determine how people value 
various factors of diseases in decision-making process for co-payment reduction. 
METHODS: We determined six factors, i.e., inﬂ uence for life-years/QOL (low/high), 
availability for medicines (yes/no), number of patients (5,000/50,000/500,000), 
disease duration (short/long) and out-of-pocket expense per 1 month (JPY10,000/
JPY100,000, USD1 = JPY90) and developed questionnaire. Ninety-six patterns are 
reduced to 26, via orthogonal methods. a total of 1163 participants ﬁ lled question-
naire via web survey system. We adopted panel-logit model to estimate odds ratios 
for each factors. RESULTS: All 6 factors signiﬁ cantly inﬂ uenced peoples’ decision-
making process. Coefﬁ cient for each factors were as follows; out-of-pocket expense: 
2.61 > inﬂ uence for QOL: 0.976 > disease duration: 0.884 > inﬂ uence for life-years: 
0.831> number of patients: 0.105 > availability for medicines: −0.18, respectively. 
Based on this estimation, when we consider characteristics of anti-rheumatoid biolog-
ics, more than 95% people think that out-of-pocket rate should be reduced. CON-
CLUSIONS: Various factors contribute to people’s attitude for co-payment reduction. 
This quantitative result would be helpful for decision-making process in national 
health insurance system.
